cefixime has been researched along with Chronic Illness in 16 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The bacteriological eradication rates of Streptococcus pneumoniae from sputum of patients experiencing acute exacerbations of chronic bronchitis (WHO definition) have been compared following therapy with either cefuroxime axetil 250 mg b." | 9.09 | Bacteriological eradication of Streptococcus pneumoniae from patients with acute exacerbations of chronic bronchitis: cefuroxime axetil versus cefixime. ( Geslin, P; Leblanc, F; Petitpretz, P; Rio, Y; Zuck, P, 1999) |
| "9) suffering from bacterial exacerbation of chronic bronchitis have been randomly treated: 79 with co-amoxiclav (amoxicillin 875 mg+clavulanic acid 125 mg) twice daily, 69 with cefixime (400 mg) once daily, and 70 with ciprofloxacin (500 mg) twice daily for an average period of 10 days." | 9.08 | Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. ( Beghi, GF; Casalini, A; Cazzola, M; Consigli, GF; Fiorentini, F; Giura, R; Madonini, V; Paizis, G; Tonna, M; Vinciguerra, A, 1995) |
| "The focus of a multicenter trial conducted in Germany was to investigate whether a 5-day short course of cefixime 400 mg was equivalent to a 10-day standard therapy of cefixime 400 mg in the treatment of acute exacerbation of chronic bronchitis (AECB)." | 9.08 | Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis. ( Lorenz, J, 1998) |
| "Patients with purulent exacerbation of chronic bronchitis were randomized to receive either a single 400-mg daily dose of cefixime or 250 mg of cephalexin, orally, four times a day." | 9.06 | Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. ( Kalbfleisch, JH; Roberson, D; Sarubbi, F; Verghese, A, 1990) |
| "In a clinical study, 40 patients suffering from acute, recurrent or chronic sinusitis were treated with cefixime." | 7.68 | [Cefixime therapy in sinusitis]. ( Jorde, W; Schata, M, 1990) |
| "Cefixime was effective in the treatment of bacterial sinus infections in adults and was well tolerated." | 6.67 | Evaluation of cefixime in the treatment of bacterial maxillary sinusitis. ( Edelstein, DR; Kimmelman, CP; Kohlbrenner, VM; Kohut, RI; Marinaccio, AT; Matthews, BL; McCaffrey, TV; Parnes, SM; Rapp, M; Rybak, LP, 1993) |
| "The bacteriological eradication rates of Streptococcus pneumoniae from sputum of patients experiencing acute exacerbations of chronic bronchitis (WHO definition) have been compared following therapy with either cefuroxime axetil 250 mg b." | 5.09 | Bacteriological eradication of Streptococcus pneumoniae from patients with acute exacerbations of chronic bronchitis: cefuroxime axetil versus cefixime. ( Geslin, P; Leblanc, F; Petitpretz, P; Rio, Y; Zuck, P, 1999) |
| "9) suffering from bacterial exacerbation of chronic bronchitis have been randomly treated: 79 with co-amoxiclav (amoxicillin 875 mg+clavulanic acid 125 mg) twice daily, 69 with cefixime (400 mg) once daily, and 70 with ciprofloxacin (500 mg) twice daily for an average period of 10 days." | 5.08 | Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. ( Beghi, GF; Casalini, A; Cazzola, M; Consigli, GF; Fiorentini, F; Giura, R; Madonini, V; Paizis, G; Tonna, M; Vinciguerra, A, 1995) |
| " We have investigated the impact on normal human intestinal flora in a 10-day course with cefetamet-pivoxil (CET, 500 mg BID) in comparison to cefixime (CFX, 400 mg qD) or cefuroxime axetil (CA, 250 mg BID) in 24 patients suffering from acute exacerbation of chronic bronchitis." | 5.08 | Betalactam therapy and intestinal flora. ( Cassetta, MI; Conti, S; Dei, R; Fallani, S; Mazzei, T; Novelli, A, 1995) |
| "The focus of a multicenter trial conducted in Germany was to investigate whether a 5-day short course of cefixime 400 mg was equivalent to a 10-day standard therapy of cefixime 400 mg in the treatment of acute exacerbation of chronic bronchitis (AECB)." | 5.08 | Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis. ( Lorenz, J, 1998) |
| "Patients with purulent exacerbation of chronic bronchitis were randomized to receive either a single 400-mg daily dose of cefixime or 250 mg of cephalexin, orally, four times a day." | 5.06 | Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. ( Kalbfleisch, JH; Roberson, D; Sarubbi, F; Verghese, A, 1990) |
| "In a clinical study, 40 patients suffering from acute, recurrent or chronic sinusitis were treated with cefixime." | 3.68 | [Cefixime therapy in sinusitis]. ( Jorde, W; Schata, M, 1990) |
| "Cefixime was effective in the treatment of bacterial sinus infections in adults and was well tolerated." | 2.67 | Evaluation of cefixime in the treatment of bacterial maxillary sinusitis. ( Edelstein, DR; Kimmelman, CP; Kohlbrenner, VM; Kohut, RI; Marinaccio, AT; Matthews, BL; McCaffrey, TV; Parnes, SM; Rapp, M; Rybak, LP, 1993) |
| "Lyme disease is a tickborne illness caused by the spirochete Borrelia burgdorferi." | 1.31 | Longterm decrease in the CD57 lymphocyte subset in a patient with chronic Lyme disease. ( Burrascano, J; Stricker, RB; Winger, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (75.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Khalim, W | 1 |
| Mwesigye, J | 1 |
| Tungotyo, M | 1 |
| Twinomujuni, SS | 1 |
| Kunel'skaya, NL | 1 |
| Gurov, AV | 1 |
| Kudriavtseva, IuS | 1 |
| Kafarskaia, LI | 1 |
| Izotova, GN | 1 |
| Dellamonica, P | 1 |
| Choutet, P | 1 |
| Lejeune, JM | 1 |
| Lucht, F | 1 |
| Morgon, A | 1 |
| Pessey, JJ | 1 |
| Portier, H | 1 |
| Veyssier, P | 1 |
| Joubert-Collin, M | 1 |
| Durgeat, S | 1 |
| Tomiyama, M | 1 |
| Marcos Sánchez, F | 1 |
| Reinoso Cobo, D | 1 |
| García Camba, L | 1 |
| Celdrán Gil, JL | 1 |
| Hefelfinger, DC | 1 |
| Matthews, BL | 1 |
| Kohut, RI | 1 |
| Edelstein, DR | 1 |
| Rybak, LP | 1 |
| Rapp, M | 1 |
| McCaffrey, TV | 1 |
| Kimmelman, CP | 1 |
| Parnes, SM | 1 |
| Marinaccio, AT | 1 |
| Kohlbrenner, VM | 1 |
| Nouvet, G | 1 |
| Benmessaoud, K | 1 |
| Cazzola, M | 1 |
| Vinciguerra, A | 1 |
| Beghi, GF | 1 |
| Paizis, G | 1 |
| Giura, R | 1 |
| Madonini, V | 1 |
| Fiorentini, F | 1 |
| Consigli, GF | 1 |
| Tonna, M | 1 |
| Casalini, A | 1 |
| Novelli, A | 1 |
| Mazzei, T | 1 |
| Fallani, S | 1 |
| Dei, R | 1 |
| Cassetta, MI | 1 |
| Conti, S | 1 |
| Lorenz, J | 1 |
| Zuck, P | 1 |
| Petitpretz, P | 1 |
| Geslin, P | 1 |
| Rio, Y | 1 |
| Leblanc, F | 1 |
| Stricker, RB | 1 |
| Burrascano, J | 1 |
| Winger, E | 1 |
| Jorde, W | 1 |
| Schata, M | 1 |
| Verghese, A | 1 |
| Roberson, D | 1 |
| Kalbfleisch, JH | 1 |
| Sarubbi, F | 1 |
10 trials available for cefixime and Chronic Illness
| Article | Year |
|---|---|
[Study of the efficacy of cefixime (suprax) in patients with acute and recurrent chronic purulent sinusitis].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Chronic Disease; Female; Humans; Male; Middle Ag | 2008 |
[Efficacy and tolerance of cefotiam hexetil in the super-infected chronic sinusitis. A randomized, double-blind study in comparison with cefixime].
Topics: Anti-Infective Agents; Cefixime; Cefotaxime; Cefotiam; Chronic Disease; Double-Blind Method; Female; | 1994 |
[The effect of cefaclor and cefixime on nasopharyngeal pathogens in children].
Topics: Acute Disease; Anti-Bacterial Agents; Bacteria; Cefaclor; Cefixime; Cefotaxime; Child; Child, Presch | 1995 |
Evaluation of cefixime in the treatment of bacterial maxillary sinusitis.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria | 1993 |
Comparative study of efficacy and safety of ciprofloxacin and cefixime in the treatment of acute exacerbations of chronic bronchitis after first-line treatment failure. French Study Group.
Topics: Aged; Anti-Infective Agents; Bronchitis; Cefixime; Cefotaxime; Chronic Disease; Ciprofloxacin; Drug | 1995 |
Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combinati | 1995 |
Betalactam therapy and intestinal flora.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria, Anaerobic; Br | 1995 |
Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis.
Topics: Administration, Oral; Bronchitis; Cefixime; Cefotaxime; Cephalosporins; Chronic Disease; Cost-Benefi | 1998 |
Bacteriological eradication of Streptococcus pneumoniae from patients with acute exacerbations of chronic bronchitis: cefuroxime axetil versus cefixime.
Topics: Adult; Aged; Aged, 80 and over; Bronchitis; Cefixime; Cefuroxime; Cephalosporins; Chronic Disease; D | 1999 |
Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Bronchitis; Cefixime; Cefotaxime; Cephalexin; Chronic Disease; Gram-Negative Bacteria | 1990 |
6 other studies available for cefixime and Chronic Illness
| Article | Year |
|---|---|
Resistance pattern of infected chronic wound isolates and factors associated with bacterial resistance to third generation cephalosporins at Mbarara Regional Referral Hospital, Uganda.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefixime; Cefoperazone; Cefpodoxime; Ceftizoxime; Cephalosporins | 2021 |
[Cefixime in the treatment of lower respiratory tract infections in patients with chronic bronchitis].
Topics: Aged; Anti-Infective Agents; Bronchitis; Cefixime; Cefotaxime; Chronic Disease; Drug Tolerance; Huma | 1995 |
Cefixime therapy for otitis media.
Topics: Acute Disease; Amoxicillin; Anti-Infective Agents; Cefixime; Cefotaxime; Child; Chronic Disease; Hum | 1993 |
[Direct costs to primary care of chronic bronchitis. Analysis of a prospective study].
Topics: Aged; Anti-Bacterial Agents; Bronchitis; Cefixime; Chronic Disease; Cohort Studies; Direct Service C | 2001 |
Longterm decrease in the CD57 lymphocyte subset in a patient with chronic Lyme disease.
Topics: Adult; Anti-Bacterial Agents; CD57 Antigens; Cefixime; Chronic Disease; Clarithromycin; Female; Huma | 2002 |
[Cefixime therapy in sinusitis].
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Cefixime; Cefotaxime; Chronic Disease; Drug Admin | 1990 |